Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indofarma Tbk. (INAF) vs Reksa Dana Premier ETF IDX30 (XIIT) Price & Performance

Indofarma Tbk.Trade
Reksa Dana Premier ETF IDX30Trade

Price performance (Past 24H)

Key statistics

Indofarma Tbk. vs Reksa Dana Premier ETF IDX30 — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Reksa Dana Premier ETF IDX30 trades at Rp470 (market cap 1.94T, 4.4K 24h volume). The key difference: Reksa Dana Premier ETF IDX30 is far larger — about 5× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.

INAFXIIT
Market Cap
390.51B1.94T
Volume
4.4K
Lot
44
Turnover
2.07M
Average Price
471.57
Value
2.07M

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INAF
View details

About Indofarma Tbk.

PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.

Read more on INAF

About Reksa Dana Premier ETF IDX30

Read more on XIIT